Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Passing one or more FDA-approved therapies next year can solve the high proportion of undiagnosed patients in the majority of young male patients and treatment compliance issues

Exton, Pennsylvania, November 16, 2021/PRNewswire/ - Spherix recently conducted a survey of 101 American gastroenterologists and conducted ten qualitative interviews (including four key industry opinions Leader’s interview) to assess current and future treatment paradigms (EoE) for eosinophilic esophagitis. The second wave of research included in Spherix’s Market Dynamix™ service focused on trend indicators for patient management, while also delving into opportunities for agents developed for indications.

From this year to last year, it became clear that gastroenterologists faced two major obstacles in treating EoE. First, gastroenterologists estimate that nearly half of EoE patients have not been diagnosed, which means that many potential patients have symptoms but have not yet taken steps to see a doctor. Survey respondents also found that increasing general awareness of EoE and its symptoms will help increase the diagnosis rate.

The second obstacle is the patient's compliance with EoE treatment. When asked to determine their challenges in treating the disease, 44% of gastroenterologists voluntarily responded with poor patient compliance.

In the qualitative interview, the doctor explained in detail that EoE is a chronic disease, but it can occasionally manifest itself. The patient is successfully treated for a period of time and then does not return for follow-up evaluation. Gastroenterologists estimate that as many as one-fifth of EoE patients may fall into this "failure and return" category. Some interviewees speculated that the characteristics of EoE patients, who are usually younger, also lead to reluctance to receive long-term treatment.

The report also confirmed that if PPI treatment fails, EoE patients are most likely to receive proton pump inhibitors (PPI) and steroid preparations (inhalation, serous). In addition, 42% of gastroenterologists said that the demand for new treatment options in EoE was not met, while the rest believed that there was at least a moderate unmet need.

Gastroenterologists are well aware of some pipeline drugs that are being developed, and most people expect that as many as two therapies will be approved for EoE in a year. Interviewees evaluated several pipeline treatments:

The Market Dynamix™ report assesses the advantages and limitations of each pipeline profile, as well as an assessment of the likelihood of prescribing and the ranking of preferred treatments.

Given that they have previously been exposed to the use of steroid preparations (through professional pharmacies) to treat patients with EoE, gastroenterologists are more aware of these treatment options and prefer these treatment options. Specifically, the combination of two steroid preparations (APT-1011, TAK-721) and the combination of four biological preparations (dupilumab, benralizumab, liretelimab, and cendakimab) resulted in the former having higher familiarity and more likely to be listed as the No. One of the most optimal pipeline therapy.

About Market Dynamix™ Market Dynamix™ is an independent service that provides market analysis that is expected to undergo a paradigm shift in the next three to five years. The insight highlights the size of the market, current processing methods, unmet needs, and expert opinions on disruptions that pipeline agents may introduce.

About Spherix Global Insights Spherix Global Insights is a highly focused market intelligence company that uses our own independent data and expertise to provide strategic guidance to enable biopharmaceutical stakeholders to make confident decisions. We focus on specific immunology, nephrology and neurology markets.

All company, brand, or product names in this document are the trademarks of their respective owners.

For more information, please contact: Eric John, Head of Gastroenterology Franchise Email: [Email Protection] www.spherixglobalinsights.com

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time